Rothman Institute, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Department of Orthopaedic Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Shoulder Elbow Surg. 2022 Dec;31(12):2457-2464. doi: 10.1016/j.jse.2022.07.020. Epub 2022 Sep 6.
COVID-19 triggered disruption in the conventional care pathways for many orthopedic procedures. The current study aims to quantify the impact of the COVID-19 pandemic on shoulder arthroplasty hospital surgical volume, trends in surgical case distribution, length of hospitalization, posthospital disposition, and 30-day readmission rates.
This study queried all Medicare (100% sample) fee-for-service beneficiaries who underwent a shoulder arthroplasty procedure (Diagnosis-Related Group code 483, Current Procedural Terminology code 23472) from January 1, 2019, to December 18, 2020. Fracture cases were separated from nonfracture cases, which were further subdivided into anatomic or reverse arthroplasty. Volume per 1000 Medicare beneficiaries was calculated from April to December 2020 and compared to the same months in 2019. Length of stay (LOS), discharged-home rate, and 30-day readmission for the same period were obtained. The yearly difference adjusted for age, sex, race (white vs. nonwhite), Centers for Medicare & Medicaid Services Hierarchical Condition Category risk score, month fixed effects, and Core-Based Statistical Area fixed effects, with standard errors clustered at the provider level, was calculated using a multivariate analysis (P < .05).
A total of 49,412 and 41,554 total shoulder arthroplasty (TSA) cases were observed April through December for 2019 and 2020, respectively. There was an overall decrease in shoulder arthroplasty volume per 1000 Medicare beneficiaries by 14% (19% reduction in anatomic TSA, 13% reduction in reverse shoulder arthroplasty, and 3% reduction in fracture cases). LOS for all shoulder arthroplasty cases decreased by 16% (-0.27 days, P < .001) when adjusted for confounders. There was a 5% increase in the discharged-home rate (88.0% to 92.7%, P < .001), which was most prominent in fracture cases, with a 20% increase in discharged-home cases (65.0% to 73.4%, P < .001). There was no significant change in 30-day hospital readmission rates overall (P = .20) or when broken down by individual procedures.
There was an overall decrease in shoulder arthroplasty volume per 1000 Medicare beneficiaries by 14% during the COVID-19 pandemic. A decrease in LOS and increase in the discharged-home rates was also observed with no significant change in 30-day hospital readmission, indicating that a shift toward an outpatient surgical model can be performed safely and efficiently and has the potential to provide value.
COVID-19 扰乱了许多骨科手术的常规治疗途径。本研究旨在量化 COVID-19 大流行对肩部关节置换术医院手术量、手术病例分布趋势、住院时间、出院后去向以及 30 天再入院率的影响。
本研究对所有接受肩部关节置换术(诊断相关组代码 483,当前程序术语代码 23472)的 Medicare(100%样本)付费服务受益人进行了查询,时间为 2019 年 1 月 1 日至 2020 年 12 月 18 日。将骨折病例与非骨折病例分开,非骨折病例进一步分为解剖或反向关节置换术。2020 年 4 月至 12 月期间计算了每 1000 名 Medicare 受益人的手术量,并与 2019 年同期进行了比较。同期获得了住院时间(LOS)、出院回家率和 30 天再入院率。使用多元分析(P<.05)计算了经年龄、性别、种族(白人与非白人)、医疗保险和医疗补助服务分层条件类别风险评分、月固定效应和核心基础统计区域固定效应调整后的每年差异,并使用标准错误聚类在提供者层面。
2019 年和 2020 年 4 月至 12 月期间,总共观察到 49412 例和 41554 例全肩关节置换术(TSA)。每 1000 名 Medicare 受益人的肩部关节置换术量总体减少了 14%(解剖性 TSA 减少 19%,反向肩关节置换术减少 13%,骨折病例减少 3%)。在调整混杂因素后,所有肩部关节置换术病例的 LOS 减少了 16%(-0.27 天,P<.001)。出院回家率提高了 5%(88.0%至 92.7%,P<.001),在骨折病例中最为明显,出院回家病例增加了 20%(65.0%至 73.4%,P<.001)。总体而言,30 天医院再入院率没有显著变化(P=.20),也没有按个别程序进行细分。
在 COVID-19 大流行期间,每 1000 名 Medicare 受益人的肩部关节置换术量总体减少了 14%。LOS 下降,出院回家率上升,30 天医院再入院率无显著变化,表明向门诊手术模式转变是安全有效的,有可能提供价值。